Post-Transplantation Diabetes Mellitus in Pediatric Patients
More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occur...
Gespeichert in:
Veröffentlicht in: | Hormone research in paediatrics 2021-04, Vol.93 (9-10), p.510-518 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 518 |
---|---|
container_issue | 9-10 |
container_start_page | 510 |
container_title | Hormone research in paediatrics |
container_volume | 93 |
creator | Grundman, Jody B. Wolfsdorf, Joseph I. Marks, Brynn E. |
description | More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients. |
doi_str_mv | 10.1159/000514988 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33789298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2507729277</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</originalsourceid><addsrcrecordid>eNpt0M9LwzAUB_AgihtzB-8iBS96qObHmh_gReaPCROLzHNJk1SiXVuT9OB_b0ZnT17yAu_zHo8vAKcIXiOUiRsIYYYWgvMDMEWUkhRzTA_HP-ITMPf-MzJIOBOIHYMJIYwLLPgU3OatD-nGycZ3tWyCDLZtknsrSxOMT15MXdvQ-8Q2SW60lcFZleRRmSb4E3BUydqb-b7OwPvjw2a5StevT8_Lu3WqCBUhXRitEONMG7jYXauzioqSKUmF4VprRVVGWckR4brCGJZMGFppHZ9MIJ6RGbgc9nau_e6ND8XWehVPk41pe1_gDDKGBWYs0quBKtd670xVdM5upfspECx2eRVjXtGe79f25dboUf6lE8HZAL6k-zBuBOP8xb_t1Vs-iKLTFfkFDK95ow</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2507729277</pqid></control><display><type>article</type><title>Post-Transplantation Diabetes Mellitus in Pediatric Patients</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Grundman, Jody B. ; Wolfsdorf, Joseph I. ; Marks, Brynn E.</creator><creatorcontrib>Grundman, Jody B. ; Wolfsdorf, Joseph I. ; Marks, Brynn E.</creatorcontrib><description>More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.</description><identifier>ISSN: 1663-2818</identifier><identifier>EISSN: 1663-2826</identifier><identifier>DOI: 10.1159/000514988</identifier><identifier>PMID: 33789298</identifier><language>eng</language><publisher>Basel, Switzerland</publisher><subject>Child ; Diabetes Mellitus - diagnosis ; Diabetes Mellitus - etiology ; Diabetes Mellitus - therapy ; Humans ; Immunosuppressive Agents - administration & dosage ; Immunosuppressive Agents - adverse effects ; Mini Review Article ; Organ Transplantation ; Postoperative Complications - diagnosis ; Postoperative Complications - etiology ; Postoperative Complications - therapy</subject><ispartof>Hormone research in paediatrics, 2021-04, Vol.93 (9-10), p.510-518</ispartof><rights>2021 S. Karger AG, Basel</rights><rights>2021 S. Karger AG, Basel.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</citedby><cites>FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</cites><orcidid>0000-0002-0193-4193 ; 0000-0002-4849-9774</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2427,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33789298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grundman, Jody B.</creatorcontrib><creatorcontrib>Wolfsdorf, Joseph I.</creatorcontrib><creatorcontrib>Marks, Brynn E.</creatorcontrib><title>Post-Transplantation Diabetes Mellitus in Pediatric Patients</title><title>Hormone research in paediatrics</title><addtitle>Horm Res Paediatr</addtitle><description>More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.</description><subject>Child</subject><subject>Diabetes Mellitus - diagnosis</subject><subject>Diabetes Mellitus - etiology</subject><subject>Diabetes Mellitus - therapy</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Mini Review Article</subject><subject>Organ Transplantation</subject><subject>Postoperative Complications - diagnosis</subject><subject>Postoperative Complications - etiology</subject><subject>Postoperative Complications - therapy</subject><issn>1663-2818</issn><issn>1663-2826</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0M9LwzAUB_AgihtzB-8iBS96qObHmh_gReaPCROLzHNJk1SiXVuT9OB_b0ZnT17yAu_zHo8vAKcIXiOUiRsIYYYWgvMDMEWUkhRzTA_HP-ITMPf-MzJIOBOIHYMJIYwLLPgU3OatD-nGycZ3tWyCDLZtknsrSxOMT15MXdvQ-8Q2SW60lcFZleRRmSb4E3BUydqb-b7OwPvjw2a5StevT8_Lu3WqCBUhXRitEONMG7jYXauzioqSKUmF4VprRVVGWckR4brCGJZMGFppHZ9MIJ6RGbgc9nau_e6ND8XWehVPk41pe1_gDDKGBWYs0quBKtd670xVdM5upfspECx2eRVjXtGe79f25dboUf6lE8HZAL6k-zBuBOP8xb_t1Vs-iKLTFfkFDK95ow</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Grundman, Jody B.</creator><creator>Wolfsdorf, Joseph I.</creator><creator>Marks, Brynn E.</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0193-4193</orcidid><orcidid>https://orcid.org/0000-0002-4849-9774</orcidid></search><sort><creationdate>20210401</creationdate><title>Post-Transplantation Diabetes Mellitus in Pediatric Patients</title><author>Grundman, Jody B. ; Wolfsdorf, Joseph I. ; Marks, Brynn E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-4edc1787de040005d5f69b7ca69e8dddc6c567b8138df220b79e6fdde6f591853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Child</topic><topic>Diabetes Mellitus - diagnosis</topic><topic>Diabetes Mellitus - etiology</topic><topic>Diabetes Mellitus - therapy</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Mini Review Article</topic><topic>Organ Transplantation</topic><topic>Postoperative Complications - diagnosis</topic><topic>Postoperative Complications - etiology</topic><topic>Postoperative Complications - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grundman, Jody B.</creatorcontrib><creatorcontrib>Wolfsdorf, Joseph I.</creatorcontrib><creatorcontrib>Marks, Brynn E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone research in paediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grundman, Jody B.</au><au>Wolfsdorf, Joseph I.</au><au>Marks, Brynn E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Post-Transplantation Diabetes Mellitus in Pediatric Patients</atitle><jtitle>Hormone research in paediatrics</jtitle><addtitle>Horm Res Paediatr</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>93</volume><issue>9-10</issue><spage>510</spage><epage>518</epage><pages>510-518</pages><issn>1663-2818</issn><eissn>1663-2826</eissn><abstract>More than 80% of pediatric solid organ transplant (SOT) recipients now survive into young adulthood and many encounter transplant-related complications. Post-transplantation diabetes mellitus (PTDM), sometimes also referred to as post-transplant diabetes or new onset diabetes after transplant, occurs in 3–20% of pediatric SOT recipients depending upon the organ transplanted, age at transplantation, immunosuppressive regimen, family history, and time elapsed since transplant. To diagnose PTDM, hyperglycemia must persist beyond the initial hospitalization for transplantation when a patient is on stable doses of immunosuppressive medications. Though standard diagnostic criteria used by the American Diabetes Association (ADA) to diagnose diabetes are employed, clinicians need to be aware of the limitations of using these criteria in this unique patient population. Management of PTDM parallels strategies used for type 2 diabetes (T2D), while also carefully considering comorbidities and potential interactions with immunosuppressive medications in these patients. In caring for patients with PTDM, it is important to be familiar with these interactions and comorbidities in order to coordinate care with the transplant team and optimize outcomes for these patients.</abstract><cop>Basel, Switzerland</cop><pmid>33789298</pmid><doi>10.1159/000514988</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-0193-4193</orcidid><orcidid>https://orcid.org/0000-0002-4849-9774</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-2818 |
ispartof | Hormone research in paediatrics, 2021-04, Vol.93 (9-10), p.510-518 |
issn | 1663-2818 1663-2826 |
language | eng |
recordid | cdi_pubmed_primary_33789298 |
source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
subjects | Child Diabetes Mellitus - diagnosis Diabetes Mellitus - etiology Diabetes Mellitus - therapy Humans Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - adverse effects Mini Review Article Organ Transplantation Postoperative Complications - diagnosis Postoperative Complications - etiology Postoperative Complications - therapy |
title | Post-Transplantation Diabetes Mellitus in Pediatric Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A18%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Post-Transplantation%20Diabetes%20Mellitus%20in%20Pediatric%20Patients&rft.jtitle=Hormone%20research%20in%20paediatrics&rft.au=Grundman,%20Jody%20B.&rft.date=2021-04-01&rft.volume=93&rft.issue=9-10&rft.spage=510&rft.epage=518&rft.pages=510-518&rft.issn=1663-2818&rft.eissn=1663-2826&rft_id=info:doi/10.1159/000514988&rft_dat=%3Cproquest_pubme%3E2507729277%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2507729277&rft_id=info:pmid/33789298&rfr_iscdi=true |